98 results
ARS
2024 FY
CCCC
C4 Therapeutics Inc
30 Apr 24
Annual report to shareholders
8:52am
clinical trials may begin; approval by an independent institutional review board, or IRB, for each clinical site or centrally before each trial may … development, as well as amendments to previously submitted clinical trials. Further, an independent IRB for each institution participating in the clinical trial
8-K
CCCC
C4 Therapeutics Inc
8 Mar 24
Departure of Directors or Certain Officers
4:10pm
alternatives, and a review of other applicable factors with the input of the Committee’s independent compensation consultant. The Committee designed
S-8
EX-23.2
CCCC
C4 Therapeutics Inc
22 Feb 24
Registration of securities for employees
9:01am
Exhibit 23.2
Consent of Independent Registered Public Accounting Firm
The Board of Directors
C4 Therapeutics, Inc.:
We consent to the use of our
S-8
EX-5.1
CCCC
C4 Therapeutics Inc
22 Feb 24
Registration of securities for employees
9:01am
the opinions set forth below. We have relied, without independent verification, on certificates of public officials and, as to matters of fact material
S-8
aq1cw6
22 Feb 24
Registration of securities for employees
9:01am
8-K
EX-99.1
r3obkiu06i4ynm
20 Nov 23
C4 Therapeutics Strengthens Board of Directors with Owen Hughes Appointment
7:05am
8-K
xbn1 hja6j7rbv0cgcn
20 Jun 23
C4 Therapeutics Appoints Leonard Reyno, M.D., as Chief Medical Officer
7:11am
8-K
EX-10.1
bx3g8pt rqoa
30 May 23
Entry into a Material Definitive Agreement
7:30am
8-K
EX-10.2
j4om1a ze1ux
30 May 23
Entry into a Material Definitive Agreement
7:30am
8-K
EX-99.1
wq9hha
30 May 23
Entry into a Material Definitive Agreement
7:30am
ARS
fice 3h9xtmjfbot74
28 Apr 23
Annual report to shareholders
7:03am
PRE 14A
ovpo23 7j9bmqiwpt
18 Apr 23
Preliminary proxy
7:59am